Siemens and pharmaceutical facilities builder Exyte have partnered to provide drugs manufacturers with digital manufacturing solutions to scale vaccine and drug production. The solutions are aimed at helping pharmaceutical companies rapidly develop and mass-produce new medicines and vaccines in response to the Covid-19 crisis. 

The two companies are providing standardised, turnkey solutions compliant with cGMP (current Good Manufacturing Practice) and GAMP (Good Automated Manufacturing Practice) to biotechnology manufacturers as well as cell and gene therapy manufacturers.  

Siemens and Exyte will offer intelligent, modular, and scalable biotech facilities. Siemens will provide solutions for process automation and digitalisation. For its part, Exyte will offer its ExyCell modular technology for rapid construction.

Currently, the first buildings with Siemens’ technology and ExyCell modules are being designed for cell and gene therapy manufacturing and biologicals production in China and Europe.

“We are excited to collaborate with Exyte to provide pre-fabricated, modular biotechnology solutions with our technology already embedded. As a market leader for the pharmaceutical industry, we offer know-how for process automation with our Simatic PCS 7 and WinCC automation platforms, as well as power supply and fire protection for modular cleanrooms,” said Eckard Eberle, CEO Siemens Process Automation.

Luca Mussati, Vice President Pharmaceuticals & Biotechnology at Exyte states: “Our partnership with Siemens enables us to pre-integrate Siemens’ technology into ExyCell modules, thus offering clients end-to-end solutions for their facilities. Our collaboration allows our clients to reap the benefits of industry 4.0 without the necessity of engineering them from scratch each time, thus saving them time and money. ExyCell modules are suitable for new buildings as well as for the retrofit of existing buildings, and can be provided either in standard, off-the-shelf plant configurations, or modules that can be combined to meet specific customer requirements.”